Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates.
Nawal Al KaabiAbderrahim OulhajSubhashini GanesanFarida Ismail Al HosaniOmer NajimHalah IbrahimJuan AcunaAhmed R AlsuwaidiAshraf M KamourAshraf AlzaabiBadreyya Ahmed Al ShehhiHabiba S AlSafarSalah Eldin HusseinJehad Saleh AbdallaDalal Saeed Naser Al MansooriAhmed Abdul Kareem Al HammadiMohammed A AmariAhmed Khamis Al RomaithiStefan WeberSantosh ElavalliIslam EltantawyNoura Khamis AlghaithiJumana Nafiz Al AzaziStephen Geoffrey HoltMohamed MostafaRabih HalwaniHanif KhalakWael ElaminRami BeiramWalid ZaherPublished in: Nature communications (2022)
The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID-19) and its long-term effectiveness have not been well characterized among the general population. We conducted a retrospective cohort study using electronic health records of 3,147,869 adults, of which 1,099,886 vaccinated individuals were matched, in a 1:1 ratio to 1,099,886 unvaccinated persons. A Cox-proportional hazard model with time varying coefficients was used to assess the vaccine effectiveness adjusting for age, sex, comorbidity, ethnicity, and the calendar month of entry into the study. Our analysis showed that the effectiveness was 79.6% (95% CI, 77.7 to 81.3) against hospitalization, 86% (95% CI, 82.2 to 89.0) against critical care admission, and 84.1% (95% CI, 70.8 to 91.3) against death due to COVID-19. The effectiveness against these severe outcomes declined over time indicating the need for booster doses to increase protection against severe COVID-19 outcomes.